bnz-1
PeptideexperimentalMulti-specific
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2018 (NCT03532958)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-15INHIBITOR
IL15 inhibitor
- Interleukin-2INHIBITOR
IL2 inhibitor
- Interleukin-9INHIBITOR
IL9 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03532958 | Phase 2 | Oct 31, 2018 | Bioniz Therapeutics |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bioniz Therapeutics | For profit | 1 | 1 | 1 | 2018 |
1 organizations
Page 1 / 1